NDATRANSDERMALSYSTEM
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ADLARITY (donepezil hydrochloride) by PharmaIN is 12. First approved in 2022.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADLARITY is a transdermal formulation of donepezil hydrochloride, an acetylcholinesterase inhibitor approved in March 2022 for Alzheimer's disease. It enhances cholinergic neurotransmission by reversibly inhibiting acetylcholinesterase, thereby increasing acetylcholine concentration and improving cognitive function. The transdermal delivery system offers improved pharmacokinetics with an extended half-life of ~70 hours compared to oral formulations.
$0.002BPart D
Peak11.8 years to LOEThe product is at peak commercial maturity with moderate Medicare spending, indicating established market presence and a mature sales and marketing infrastructure.
Mechanism of Action
12.1 Mechanism of Action Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer's disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function.…
Worked on ADLARITY at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.